Search research articles
Contact Us
Filters
Showing results (1131-1140 of 1,226) with videos related to
Page
of 123
Sort By:
Antimicrobial Agents and Chemotherapy
|
January 27, 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542
Jeffrey M Jacobson, Robert J Israel, Israel Lowy, et al.
AIDS Research and Human Retroviruses
|
March 4, 2016
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1
Jeffrey M Jacobson, Steven E Bosinger, Minhee Kang, et al.
The American Journal of Gastroenterology
|
September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
Philippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
The Journal of Infectious Diseases
|
August 10, 2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
Jeffrey M Jacobson, R Pat Bucy, John Spritzler, et al.
Nature Communications
|
June 30, 2021
Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV
Leila B Giron, Clovis S Palmer, Qin Liu, et al.
Hepatology (Baltimore, Md.)
|
July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
David Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
Plos One
|
April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
Open Forum Infectious Diseases
|
September 10, 2024
Impact of the Coronavirus Disease 2019 Pandemic on Substance Use Disorder Risk Among People Living With Human Immunodeficiency Virus (HIV) Enrolled in HIV Care in the United States: An Interrupted Time Series Analysis
Jennifer P Jain, Megan J Heise, Nadra E Lisha, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 2009
Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection
Constantinos Petrovas, Benjamin Chaon, David R Ambrozak, et al.
The New England Journal of Medicine
|
April 12, 2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
Stefan Zeuzem, Ira M Jacobson, Tolga Baykal, et al.
Page
of 123
Search research articles
Search
Showing results (1131-1140 of 1,226) with videos related to
Sort By:
Page
of 123
Antimicrobial Agents and Chemotherapy
|
January 27, 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542
Jeffrey M Jacobson, Robert J Israel, Israel Lowy, et al.
AIDS Research and Human Retroviruses
|
March 4, 2016
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1
Jeffrey M Jacobson, Steven E Bosinger, Minhee Kang, et al.
The American Journal of Gastroenterology
|
September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
Philippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
The Journal of Infectious Diseases
|
August 10, 2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
Jeffrey M Jacobson, R Pat Bucy, John Spritzler, et al.
Nature Communications
|
June 30, 2021
Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV
Leila B Giron, Clovis S Palmer, Qin Liu, et al.
Hepatology (Baltimore, Md.)
|
July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
David Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
Plos One
|
April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
Open Forum Infectious Diseases
|
September 10, 2024
Impact of the Coronavirus Disease 2019 Pandemic on Substance Use Disorder Risk Among People Living With Human Immunodeficiency Virus (HIV) Enrolled in HIV Care in the United States: An Interrupted Time Series Analysis
Jennifer P Jain, Megan J Heise, Nadra E Lisha, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 2009
Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection
Constantinos Petrovas, Benjamin Chaon, David R Ambrozak, et al.
The New England Journal of Medicine
|
April 12, 2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
Stefan Zeuzem, Ira M Jacobson, Tolga Baykal, et al.
Page
of 123